🇺🇸

US SEC Filing Intelligence

· daily

US Executive Compensation Proxy SEC Filings — April 29, 2026

Across 50 DEF 14A proxy statements filed around April 29, 2026, for June 2026 annual meetings, a dominant theme is robust 2025 financial performance in high-materiality filings, with 12 companies reporting YoY revenue growth averaging 22% (e.g., Xometry 26%, Matador 21% BOE), margin expansions (Xometry +120 bps to 34.7%), and strong capital returns ($2.5B dividends at Fidelity, $98M buybacks at Terex). Biotech and healthcare sectors dominate (25+ filings), highlighting pipeline progress (United Therapeutics ADVANCE/TETON studies, ARS Pharma neffy launch with 22,500+ prescribers) and M&A (Penumbra $14.5B deal, CorMedix Melinta acquisition driving rev to $311.7M from prior loss). Neutral sentiment prevails (70%), but positive in 20% tied to record results and TSR (United Therapeutics 38%), with mixed cases like C4 Therapeutics halting CFT1946 and WisdomTree PEO CAP down 35% YoY. Capital allocation favors buybacks/dividends (Matador div up to $1.50, $55.8M repurchases) over reinvestment, signaling management conviction amid no widespread insider selling. Virtual meetings are standard (90%+), with common proposals for director elections, say-on-pay (annual frequency recommended), auditor ratifications, and equity plan expansions; portfolio-level trend shows outperformance vs. broader market in growth sectors, but watch comp votes for governance risks.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — April 29, 2026

The IPO Pipeline stream reveals a surge in SPAC activity with two blank-check companies (Aussie Aussie Acquisition Corp and GSR V Acquisition Corp) filing S-1s for $100M and $200M unit IPOs respectively, targeting U.S. business combinations within 18-21 months, signaling renewed investor interest in SPACs amid neutral sentiment. Brink’s Company (BCO) S-4 highlights a major M&A deal acquiring NCR Atleos (NATL) at $50.40/share implied value (cash $30 + 0.1574 BCO shares), with positive sentiment and post-merger 22% ownership for NATL holders, potentially accretive for security/ATM sectors. Direct Digital Holdings (DRCT) S-1 enables resale of 20M shares post 4:1 reverse split, with stock at $2.87, indicating potential capital raise up to $50M but raising dilution concerns. Absent operational metrics or period comparisons in these pre-operational/registration filings, themes center on SPAC resurgence, reverse splits in ad tech, and strategic M&A; no insider activity or capital allocation details noted. Market implications include near-term SPAC pricing catalysts, merger vote risks, and opportunities for arbitrage in undervalued targets.

4 high priority 4 total filings
· daily

Global High-Priority Regulatory Events — April 29, 2026

Across 50 filings in the 'Global High Priority Market Events' stream, dominant themes include regulatory compliance lapses and fines in Indian firms (e.g., SGL Resources, Gratex), insolvency and default escalations (CMI, MT Educare, Dharani Sugars), alongside robust M&A activity (Woori Financial, Mission Produce, D. Boral ARC SPAC) and buybacks (Windlas Biotech, Rolex Rings). Q1 2026 US earnings show mixed results with standout revenue growth in Bloom Energy (+130% YoY), Visa (+17% YoY), Vulcan Materials (+7% YoY), but margin compressions and net losses in others like SiteOne, Sysco (-9.1% operating income). Aggregate revenue trends: 18/30 reporting companies saw YoY growth averaging +25% (outliers Bloom +130%, JinkoSolar -29%), but net income mixed with 12/25 declining (avg -15%). Capital returns strong via buybacks/repurchases in 8 firms (e.g., SiteOne $20M, Anika $15M) and dividends. Forward catalysts cluster in May-Jun 2026 (buybacks, AGMs, CoC meetings), signaling takeover risks in India and AI/M&A opportunities globally. Portfolio implication: overweight defensive capital return plays, monitor insolvency contagion in small-caps.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — April 29, 2026

Across 50 Q1 2026 10-Q filings, companies reported mixed results with aggregate revenue growth averaging ~15% YoY (e.g., Omnicom +69%, Bloom Energy +130%, Visa +17%), driven by sectors like advertising, energy, payments, and midstream, but offset by widespread margin compression (e.g., Sysco operating income -9.1%, GE HealthCare -18%) due to rising operating expenses (+10% avg in many), restructuring, and impairments. Capital allocation emphasized shareholder returns with buybacks (e.g., Visa $11.7B, Omnicom $2.8B annualized pace) and dividends (e.g., Welltower +10% YoY), alongside aggressive M&A (e.g., Veralto $426M, Parsons $334M, GE HealthCare $2.3B). Cash balances declined QoQ in 70% of filers (avg -20%), signaling working capital strains and investment outflows, while total assets grew in 60% via acquisitions/goodwill. Sentiment was mixed in 98% (negative in MGP Ingredients due to $180M impairment), highlighting cost pressures amid growth. Portfolio-level trends point to resilient top-line but profitability risks; utilities/finance showed stability, pharma/energy outliers in growth. No major guidance changes noted, but M&A integration and Q2 earnings calls loom as catalysts. Implications: Favor high-conviction buyback names; trim margin squeezes.

50 high priority 50 total filings
· daily

US SEC Trading Suspension Halt Orders — April 29, 2026

Four small-cap companies on Nasdaq Capital Market (SGMO, IVF, VSTD, RVYL) disclosed critical compliance failures on April 23-28, 2026, triggering trading suspension risks and delisting threats under Nasdaq rules. Common themes include bid price deficiencies (SGMO), untimely 10-K/10-Q filings due to restatements (IVF, VSTD), and stockholders' equity shortfalls (RVYL), with no enriched period-over-period financial trends available indicating underlying operational weaknesses rather than growth. SGMO faces imminent suspension on May 5, 2026, shifting to OTCQB, while others pursue appeals or compliance plans amid mixed resolutions like RYVYL's $20M+ merger boost. Market implications: heightened volatility, liquidity erosion, and short-term trading halts for microcaps, signaling broader small-cap distress without positive YoY/QoQ revenue or margin expansions. Portfolio-level pattern: 100% of filings show regulatory halts tied to prolonged non-compliance (e.g., SGMO's two failed periods ending Oct 2025/Apr 2026), urging avoidance of longs in similar profiles.

4 high priority 4 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 29, 2026

Across 43 filings in the USA Corporate Distress & Bankruptcy stream, a mixed landscape emerges with 7 clear distress signals (delistings, late filings, Nasdaq deficiencies) countered by robust M&A activity (7 deals valued $130M-$1.9B) and financing amendments (12+ credit facilities/loans totaling billions), suggesting restructurings and strategic pivots amid challenges. Period-over-period trends are sparse but highlight Vulcan Materials' outlier strength (+7% YoY revenue to $1.756B, +16% gross profit, +9% adj EBITDA at 25.5% margin) vs. flat/declining peers; no widespread margin compression but settlement burdens like Atkore's $136.5M hit. Forward-looking catalysts cluster in Q3 2026 (multiple M&A closings, e.g., OppFi, KalVista, TWO Harbors), with Nasdaq appeals/hearings in May. Capital allocation leans defensive (divestitures like Aterian $18M sale, Vulcan $217M returns) over aggressive buybacks/dividends. Portfolio-level patterns show microcaps/pharma/tech dominant in distress (Sangamo delisting, INVO/Vestand late 10-Ks), while banks/fintech pursue accretive acquisitions (OppFi +25% EPS 2027, Hawthorn +20% EPS). Implications: Opportunistic M&A in distress names offers turnaround alpha, but monitor compliance risks for short volatility.

43 high priority 43 total filings
· daily

US Executive Officer Management Changes SEC — April 29, 2026

Across 30 SEC filings on USA Executive & Director Changes dated April 29, 2026, the dominant theme is neutral transitions with 70%+ involving retirements, non-re-elections, or planned departures without disagreements (e.g., Tri-State CAO, Sprinklr directors, Vertex CFO nominee), signaling board refreshments amid stability. Positive appointments and planned successions in banking (Hawthorn Bancshares, City Holding, First Mid Bancshares, Kinsale) and biotech/tech (Olema Pharma, Rambus CFO) highlight strategic enhancements, comprising 25% of filings. Financial enriched data shows strong revenue growth where reported (Anika Therapeutics +13% YoY to $29.6M, Plexus +19% YoY to $1.164B record, Telos Q1 prelims above March guide), but mixed margins (Anika gross +810 bps to 64.2%, Plexus GAAP operating to 4.1-4.5% Q3 guide down from 5.3%). High materiality events (9/10) include Telos CEO medical leave with strong prelims, Southern Copper CEO passing, Anika $15M repurchase amid director exits, and First Mid $6.5B asset growth under transition. Capital allocation leans shareholder-friendly (Anika repurchase at $10.76 avg, AutoNation/Fastenal equity plans approved >90%). Portfolio-level: Low disruption risk (no ops impacts noted), outperformance in revenue growers vs. neutral peers, watch Q2 catalysts like Plexus FCF $50-75M FY26 target.

30 high priority 30 total filings
· daily

US Corporate Board Director Changes SEC Filings — April 29, 2026

Across 30 SEC filings focused on USA boardroom changes from April 29, 2026, overarching themes include a wave of director retirements/not standing for re-election ahead of 2026 annual meetings (e.g., Anika, Sprinklr, Vertex, MapLight, Forward Air), planned C-suite transitions/retirements (e.g., Tri-State CAO Dec 2026, Nextpower CLO July 2026, Yelp CTO June 2026), and positive appointments in banking/biotech (Hawthorn, City Holding, Olema, Rambus). Period-over-period trends show strong revenue growth in select firms (Anika +13% YoY to $29.6M, Plexus record +19% YoY to $1.164B), margin expansions (Anika +814bps to 64.2%), but also GAAP losses (Anika widened to $5.1M due to severance) and guidance for margin compression (Plexus Q3 4.1-4.5%). Capital allocation highlights include Anika's $15M buyback at $10.76/share and Plexus FY26 FCF $50-75M target. Mixed sentiment prevails (e.g., Telos CEO leave but Q1 beat), with banking sector showing bullish governance enhancements amid growth. Market implications: Opportunities in banks/biotech with experienced adds, risks in abrupt transitions (Southern Copper CEO death, Telos medical leave, Twin Hospitality bankruptcy interim), signaling potential volatility around AGMs and earnings catalysts.

30 high priority 30 total filings
· daily

US Merger & Acquisition SEC Filings — April 29, 2026

The 9 filings reveal a surge in SPAC M&A activity, with 7/9 involving acquisition corporations at various stages: new IPO (Irenic), completed no-redemption milestone (Willow Lane), extensions (GP-Act III adjourned to May 6, Constellation to May 29), updated presentations (D. Boral ARC, Spring Valley), and financing (UY Scuti note). Suncrete completed a strategic acquisition of Hope Concrete, expanding into Texas/Louisiana with retained expert operators, signaling construction sector consolidation in Sunbelt. Green Brick reported mixed Q1 2026 results with net income -18.8% YoY to $60.9M, revenues -5.9% YoY, but standout 28.9% gross margins (highest among peers, +320 bps adjusted) and 95.2% YoY financial services growth; share repurchases of $7.2M underscore confidence amid backlog drop (-34.8% YoY). Overarching themes include SPAC deadline pressures with mixed shareholder support, positive deal completions/progress, and no broad insider activity noted. Portfolio-level: SPACs dominate (78%), construction M&A active; implications favor monitoring catalysts like adjourned votes and S-4 progress for de-SPAC upside, while Green Brick's restatement (no net income impact) warrants scrutiny.

9 high priority 9 total filings
· monthly

US Pre-Market SEC Filings Roundup — April 29, 2026

Overnight SEC filings reveal mixed Q1 2026 earnings across 50 companies, with standout revenue growth in AI/tech (Teradyne +87% YoY, Bloom Energy +130% YoY) and industrials (Constellium +24% YoY), but margin pressures in consumer/retail (Stanley Black & Decker EBITDA margin -50 bps, Yum China SSS flat) and healthcare (Humana Adjusted EPS -10.9% YoY). Portfolio-level trends show 18/25 reporting companies with YoY revenue growth averaging +25%, but only 9/25 with margin expansion (avg +50 bps where positive); capital returns strong via buybacks ($2.8B Visa, $20M SiteOne) and dividends. M&A momentum builds with approvals (Mission Produce/Calavo closing July 2026, Woori/Tongyang Aug 11), while regulatory resolutions (RYVYL SEC settlement, MultiSensor Nasdaq compliance) reduce overhangs. Guidance mostly affirmed/raised (Bunge EPS to $9-9.50, Constellium EBITDA $900-940M), signaling resilience amid macro softness. Key implication: Rotate into AI/industrials outperformers, monitor healthcare/financials for further guide cuts.

23 high priority 27 medium 50 total filings
· daily

Biotech Small-Cap Approvals — April 28, 2026

The April 28, 2026 period captured 10 FDA approvals classified as 'Other' (FALLBACK type), with 0 NMEs, 0 biosimilars, and 0 label expansions, all rated neutral signals at 5/10 strength and materiality. These span diverse sponsors including APOTEX (dual approvals for ASCORBIC ACID), TEVA PHARMS USA INC (BUDESONIDE), CIPLA (ALBUTEROL SULFATE), and others, covering commodity small-molecule generics in respiratory, cardiovascular, GI, psychiatric, and vitamin categories with no dominant therapeutic area clustering. Highest-conviction signal is APOTEX's dual ASCORBIC ACID approvals on 2026-04-21, implying manufacturing redundancy and potential supply positioning in the commoditized vitamin C market but limited by neutral rating and NOT_DISCLOSED commercial metrics. No IRA exposure or exclusivity details provided, underscoring low innovation content. Key risk/watch item: Intensifying generic competition across multiple entrants, potentially pressuring margins in low-barrier segments absent pricing power data.

10 total filings
· daily

Big Pharma Approvals — April 28, 2026

The April 28, 2026 period featured 3 Other approvals (0 NMEs, 0 biosimilars, 0 label expansions) exclusively from big pharma sponsors, delivering uniformly bullish signals with no bearish or neutral readouts. AstraZeneca AB's ANIFROLIMAB-FNIA (SAPHNELO) NME approval emerges as the highest-conviction event at 8/10 strength and materiality, underscoring premium commercial potential via first-in-class exclusivity. Merck Sharp Dohme's PEMBROLIZUMAB (KEYTRUDA QLEX) and Genentech's PERTUZUMAB (PERJETA) label expansions provide steady portfolio extensions at 5/10 each, reinforcing sponsor execution. No dominant therapeutic area theme is evident from the data. Key risk/watch item: absence of disclosed peak sales, exclusivity, pricing power, and market position details limits near-term valuation precision.

3 total filings
· daily

Orphan Drug Approvals — April 28, 2026

The FDA approval period from April 28, 2026 to April 28, 2026 featured 1 orphan drug approval in the 'other' category (0 NMEs, 0 biosimilars, 0 label expansions), signaling modest activity in the sector. Kyowa Kirin's BUROSUMAB-TWZA (CRYSVITA) received a bullish label expansion approval (strength 5/10, materiality 5/10), representing the highest-conviction signal with potential to enhance the sponsor's orphan portfolio despite NOT_DISCLOSED commercial metrics. No dominant therapeutic area theme emerged from the single approval. This event underscores steady execution for Kyowa Kirin in rare diseases, though lacking pipeline breadth. Key risk/watch item: monitor near-term commercial uptake and market position given limited disclosed data.

1 total filings
· daily

New Drug Approvals (Original) — April 28, 2026

The April 28, 2026 FDA approval snapshot features 11 Other approvals (0 NMEs, 0 biosimilars, 0 label expansions per mix, though individual data notes 1 NME and multiple generic-like entries), dominated by neutral generic approvals from sponsors like APOTEX, TEVA PHARMS USA INC, and CIPLA, with no clear therapeutic area clustering. The highest-conviction signal is the bullish NME approval of ANIFROLIMAB-FNIA (SAPHNELO) by ASTRAZENECA AB, signaling a strong commercial entry with high strength (8/10) and materiality (8/10) for their immunology portfolio. These generic approvals (e.g., BUDESONIDE by TEVA PHARMS USA INC, ALBUTEROL SULFATE by CIPLA) are neutral, reflecting commoditized market entries with limited upside or downside absent originator erosion details. Key risk/watch item: Monitor originator revenue impacts from generic entrants like ESCITALOPRAM OXALATE (MICRO LABS) and PANTOPRAZOLE SODIUM (SHUANGCHENG), though no bearish signals flagged.

11 total filings
· daily

Federal Construction & Infrastructure Contracts — April 28, 2026

Fisher Sand & Gravel Co. was awarded an $847,040,000 firm-fixed-price delivery order by U.S. Customs and Border Protection (DHS) for Southwest Border Construction in San Diego, CA, comprising the full obligation in this civilian-only digest (0/1 defense-related). This large-scale infrastructure project underscores DHS/CBP's priority on border facilities under NAICS 236220, providing a bullish signal for construction contractors with a 2.3-year performance period from April 26, 2026, to August 31, 2028. The highest-conviction signal is the significant future revenue stream for Fisher Sand & Gravel Co., estimated at $356M annually. However, high pricing risk inherent in firm-fixed-price terms poses execution challenges. Key watch item: total outlayed progress from current $0 under full and open competition after exclusion of sources.

1 total filings
· daily

DHS Homeland Security Contracts — April 28, 2026

DHS awarded a single $847,040,000 firm fixed price delivery order to Fisher Sand & Gravel Co for Southwest Border Construction in San Diego, CA, representing 100% civilian obligations with 0/1 defense-related contracts. U.S. Customs and Border Protection (CBP) dominates as the agency theme, focusing on commercial and institutional building construction (NAICS 236220) over a 2.3-year performance period from April 26, 2026, to August 31, 2028. The highest-conviction bullish signal is the massive future revenue stream for Fisher Sand & Gravel Co, a non-small business Subchapter S Corporation, under full and open competition after exclusion of sources. Key risk is high pricing/execution risk inherent in the firm fixed price structure with $0 outlayed to date. Investors should watch total outlayed progress and performance milestones toward the 2028 end date.

1 total filings
· daily

New Federal Contractors — April 28, 2026

A single $847,040,000 firm fixed price delivery order awarded to Fisher Sand & Gravel Co by U.S. Customs and Border Protection (DHS) dominates this period's new federal contracts, representing 100% civilian spending with zero defense-related activity. The contract funds SW Border Construction in San Diego, CA, over a 2.3-year performance period from April 26, 2026, to August 31, 2028, signaling robust DHS/CBP infrastructure priorities. Highest-conviction bullish signal for Fisher Sand & Gravel Co as a major future revenue stream in NAICS 236220 commercial building construction. Key risk is high pricing/execution exposure under firm fixed price terms with $0 outlayed to date. Investors should monitor total outlayed progress and performance milestones toward the 2028 end date amid full and open competition dynamics.

1 total filings
· daily

Significant Contract Modifications ($10M+) — April 28, 2026

The single contract in this period represents a $847,040,000 total obligation, entirely civilian with 0/1 defense-related, focused on DHS/CBP border infrastructure. Fisher Sand & Gravel Co secured a firm fixed price delivery order for SW Border Construction in San Diego, CA, spanning April 26, 2026, to August 31, 2028, signaling a major ~$356M annual revenue stream for this non-small business construction firm (NAICS 236220). The highest-conviction bullish signal is the full obligation value under full and open competition after exclusion of sources, providing durable multi-year revenue visibility. A key risk is the high pricing risk inherent in the firm fixed price structure with $0 outlayed to date, vulnerable to cost overruns during the 2.3-year performance period. Watch total outlayed progress and any modifications to the $847M obligation.

1 total filings
· daily

Contract Deobligations Alert — April 28, 2026

A single $847,040,000 firm fixed price delivery order was awarded to Fisher Sand & Gravel Co by U.S. Customs and Border Protection (DHS) for SW Border Construction in San Diego, CA, representing 100% civilian obligations with 0 defense-related contracts. This dominant DHS/CBP infrastructure theme signals a major future revenue stream for the non-small business contractor over a 2.3-year performance period from April 26, 2026, to August 31, 2028. The highest-conviction bullish signal stems from the full and open competition award after exclusion of sources, with no outlays to date. Key watch item is total outlayed progress from the current $0 baseline amid high contract pricing risk on the firm fixed price terms.

1 total filings
· daily

Contract Option Exercises — April 28, 2026

A single $847,040,000 firm fixed price delivery order awarded to Fisher Sand & Gravel Co by U.S. Customs and Border Protection (DHS) dominates this period's contract exercises, representing 100% civilian spending with 0 defense-related awards. The order funds SW Border Construction in San Diego, CA, over ~2.3 years from April 26, 2026, to August 31, 2028, signaling bullish conviction for DHS/CBP infrastructure buildout via full and open competition. Highest-conviction signal is the massive future revenue stream for Fisher Sand & Gravel Co, estimated at $356M annually. Key risk is high pricing/execution exposure under firm fixed price terms with $0 outlayed to date, warranting close monitoring of spending progress.

1 total filings